Celularity Faces Debt Default and Executive Departures Amidst Strategic Realignment and $13.3M Asset Sale
CELU sits 20% above its 52-week low of $1.01 on light trading volume (0.2× avg).
Summary
Celularity Inc. announced the closing of a $13.3 million asset sale and debt retirement, but simultaneously disclosed a debt default due to its failure to file its annual 10-K report, alongside the departure of two senior executives.
Key Events · Legal and Risk Events · CELU
-
Asset Sale Finalized with NexGel
Celularity Inc. closed an amendment to its asset purchase and exclusive license agreement with NexGel, Inc., receiving $8.3 million in upfront cash and a $5.0 million convertible promissory note, totaling $13.3 million. This transaction also enabled the retirement of nearly $13.0 million in debt.
-
Debt Default Declared for Late 10-K Filing
Helena Global Investment Opportunities 1 Ltd. issued a default notice on a $1.97 million convertible promissory note. The default was triggered by Celularity's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. If not cured within five business days, the mandatory default amount of 115% of the principal and increased interest rates could be applied.
-
Senior Executive Departures
As part of an organizational realignment, John R. Haines, Senior Vice President, Global Manager and Chief Administrative Officer, was terminated, and Stephen A. Brigido, President, Degenerative Diseases, resigned from their positions.
Analysis · CELU · Life Sciences
This filing presents a mixed but predominantly negative signal for Celularity. While the company successfully finalized an amendment to its asset purchase agreement with NexGel, securing $13.3 million in consideration and retiring $13.0 million in debt, this positive development is overshadowed by a critical debt default. The default on a $1.97 million convertible promissory note, triggered by the company's failure to timely file its Annual Report on Form 10-K, poses a significant financial and compliance risk. Failure to cure this default could lead to accelerated payments at a premium and further erode investor confidence. The executive departures, though framed as part of a strategic realignment, add to the uncertainty surrounding the company's leadership during this challenging period. Investors should closely monitor the company's ability to cure the default and file its overdue 10-K, as these are critical for its continued operations and listing status.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.8M. The 52-week trading range was $1.01 to $4.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.